Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …

The gastrointestinal tract plays a role in the development and treatment of metabolic
diseases. During a meal, the gut provides crucial information to the brain regarding …

Gut bacteria play an important role in the digestion of food, immune activation, and
regulation of entero-endocrine signaling pathways, but also communicate with the central …

I. INTRODUCTION 1877 II. STUDYING THE... 1881 III. MICROBIOTA-GUT-BRAIN AXIS...
1907 IV. PATHWAYS OF COMMUNICATION 1911 V. MICROBIOTA AND SYNAPTIC... 1929 …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-
related glycemic excursions through augmentation of insulin and inhibition of glucagon …

Abstract Glucagon-like peptide-1 (GLP-1) controls islet hormone secretion, gut motility, and
body weight, supporting development of GLP-1 receptor agonists (GLP-1RA) for the …

Obesity is a global epidemic characterized by energy disequilibrium, metabolic disorder, fat
mass development, and chronic low-grade inflammation, which significantly affects the …

Objective A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to
determine whether the metabolic action of GIP adds to the established clinical benefits of …

The cardiovascular complications contribute to a majority of diabetes associated morbidity
and mortality, accounting for 44% of death in those patients with type 1 diabetes mellitus …